Press releaseGlobe Newswire
LeonaBio
LONA · NASDAQ
$5.27+$0.22 (+4.36%)TodayMarket closed ·
Prev close $5.05
Latest news
- Press releaseGlobe Newswire
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
- Press releaseGlobe Newswire
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
- Press releaseGlobe Newswire
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
- Press releaseGlobe Newswire
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data
- Press releaseGlobe Newswire
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.